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Submitted Jun 19, 2012; accepted Sep 8, 2012.DISCUSSIONDr Julie Freischlag (Baltimore, Md). This is a retrospective anal-
ysis in a small group of patients. Did you determine whether either of
the groups of patients would have been a candidate for the other
graft? Would the HeRO patients have been qualiﬁed for the LEAVG
graft? Is there a need to do a prospective randomized trial or are you
convinced you know which ones should get which graft?
Dr Samuel N. Steerman. Agreed. There are limitations in
this study due to the retrospective nature. We weren’t able to
determine if the patients would have been an appropriate candidate
for the alternate device in our chart review.
One of the problems is not everyone had preoperative ankle-
brachial indexes to determine suitability for LEAVG. Another
problem is although we were able to identify the weight of the
patient and the body mass index, we were not able to determine
whether a patient was acceptable for a thigh graft from a retrospec-
tive chart review. There are clearly patient factors that cannot be
ascertained from reviewing the record, similar in the way that
you can’t determine if a patient is a good candidate for peritoneal
dialysis by a retrospective chart review.
I think this is a promising study that shows some outcomes,
but a prospective randomized study is indicated to really make
some recommendations moving forward on this issue.
Dr Amy Reed (Hershey, Pa). Some of the challenges I think
with this device is the connector piece and the ﬂow dynamics
that change with that when you go from the graft to the catheter.
There have been a few anecdotal reports and some posters pre-
sented at other meetings about use of clopidogrel with these
patients. So I just wondered if any of the patients have had some
different antiplatelet therapy after placement of the HeRO?
Dr Steerman. Thank you for bringing that up. The HeRO
grafts have been associated with increased patency with the use
of clopidogrel. We were able to ﬁnd a similar association; however,
when we split up the patients who were on antiplatelet and those
who were not, we were not able to have a strong enough power to
show a difference in life-table analysis. The association was repli-
cated in this analysis, and we continue to recommend clopidogrel
after HeRO placement.
Dr Harry Schanzer (New York, NY ). We recently presented
at the VASA meeting our experience with the HeRO device in
a smaller population with end-stage vascular access. All of the
patients had had multiple AV accesses in both upper and lower
extremities and presented with central vein stenosis/occlusion.At 6 months, our primary patency was 36.4% and secondary
patency was 54.5%. At 1 year, the primary patency was 9.1% and
secondary patency was 45.5%. Our conclusion was that in order
to obtain a useful utilization of this device, a very aggressive
approach to maintaining secondary patency was required.
My question to you is: since we know that the patency rates
are so low, is there any point in using from the time of implanta-
tion aggressive anticoagulation therapy with Coumadin?
Dr Steerman. I think that’s an interesting point. We looked at
the patients who were on warfarin and did not ﬁnd an association
with improved patency; however, I do not believe we have power
to make any recommendations based on that. It could be some-
thing that could be looked at in the future, but this study was
not able to draw any signiﬁcant conclusions on anticoagulation
recommendations.
Dr Anil Hingorani (Brooklyn, NY ). Your analysis is very inter-
esting, and you’re raising very important questions for a relatively
new device. My concern, however, is you looked at the primary,
secondary patencies and the complications, but there is no real
cost analysis. I’m concerned that this device may actually be so costly
in terms of the initial placement of the device and then subsequent
reinterventions that it may not be cost effective to use it at all.
Dr Steerman. I can give you some data on that; however, it is
beyond the scope of our paper. The grafts that were implanted in
the thigh range from a cost of $700 to approximately $900 just for
the device. For the HeRO, the device cost is $2300, and that’s
prior to performing any adjunct procedures that are necessary or
factoring in any endovascular balloons used to implant the device
or ﬂuoroscopy costs.
In addition, the increased intervention rate also contributes to
the cost of the HeRO device.
If we are speaking of cost, we must also consider the expense
of a hospitalization due to catheter-related bloodstream infection.
Both of these devices reduce the risk of this expense and the
morbid complications of dialysis catheters.
Dr Christopher Carsten (Greenville, SC). Since my partner,
David Cull, and I presented the original series that you were
kind enough to quote frequently, we’ve transitioned to placing
most of our grafts based off of the mid thigh and avoided the groin
and have had much improved results in regards to infection. Do
you all have any experience placing your grafts off of lower than
the groin crease?
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reported basing the graph off of the superﬁcial femoral artery and
femoral vein; however, the exact location with the thigh could not
be clearly elucidated. We did report several straight grafts that were
placed from the popliteal artery to the femoral vein, which may
avoid a larger groin incision and perhaps decrease infection. I
appreciate your comment; this may be a good option for patients
with a redundant abdominal pannus.
Dr Patrick Mahon (Manchester, NH). Did you look at the
failure mode of your HeRO grafts and connect that to where
the distal HeRO was, whether you were placing it because you
had axillary subclavian occlusion and you had to put it in the
central circulation, or do you have central occlusion in the innom-
inate vein and you had to put it in the heart? And was there prob-
lems with stenosis in the outﬂow tract or just clotting off because
of the long outﬂow tract?Dr Steerman. The patient that is typically selected for HeRO
implantation has venous drainage that isn’t enough to support an
upper extremity access. Whether the central venous obstruction
was subclavian, axillary, or central stenosis wasn’t clearly delineated
in the review. Our preference is to place the device through the
internal jugular vein, and the outﬂow tract really doesn’t depend
on a patent axillary or subclavian vein, it only depends on a patent
vein where the tip of the outﬂow component is positioned. So this
wasn’t delineated in our study.
The failure mode of the HeRO was not found to be due to
stenosis within the outﬂow component. The nitinol reinforcement
of the catheter seemed to protect the device from this complication
in our series. The graft component did develop some areas of in-
graft stenosis in some of the cases where the graft thrombosed.
And in some cases no underlying lesion was found, and we weren’t
able to identify the cause of the thrombosis.
